Bio-Rad last week appointed Louis Drapeau to its audit committee. He will stand for election at a board meeting in April. Drapeau fills the space left open by the death late last year of Philip Padou.
 
Drapeau is currently CFO and senior vice president of finance at Nextar Therapeutics. He also served as CEO, CFO, and senior vice president at BioMarin Pharmaceutical, and was an executive in accounting and he serves on the board of directors at Inflazyme Pharmaceuticals.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.